Investigational immunotherapy; protocol suggests it is a CD137 (4-1BB) costimulatory agonist, likely a monoclonal antibody that activates cytotoxic T cells and NK cells.
ZL-1310 is an anti-DLL3 antibody-drug conjugate. It binds DLL3 on tumor cells (e.g., SCLC), is internalized, and delivers a linked cytotoxic payload that induces death of DLL3-expressing cells.
YES
DIRECT
ADC binds DLL3 on tumor cells, is internalized, and releases a cytotoxic payload inside the cell, causing death of DLL3-expressing cells.
An autologous, genetically engineered anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are modified to express a CD19-specific CAR with CD28 costimulatory and CD3ζ signaling domains. Administered as a single infusion of CAR-positive viable T cells (target 2×10^6 cells/kg; maximum 2×10^8 cells). Upon CD19 engagement on B cells, CAR T cells activate cytotoxicity, proliferate, and release cytokines, leading to depletion of CD19+ lymphoma cells.
Autologous T cells are engineered to express a CD19-specific chimeric antigen receptor with CD28 costimulatory and CD3ζ signaling domains. Upon binding CD19 on B cells, the CAR T cells activate, proliferate, release cytokines, and kill target cells via cytotoxic mechanisms (perforin/granzyme), resulting in depletion of CD19+ lymphoma cells.
YES
DIRECT
CD19-specific CAR T cells bind CD19 on target B cells, form an immunologic synapse, and kill via perforin/granzyme-mediated cytolysis and death-receptor apoptosis.
An antibody-drug conjugate (STRO-002, Luvelta) targeting folate receptor-α (FOLR1). It consists of an anti-FOLR1 IgG1 (SP8166) linked via a cathepsin-cleavable linker to a 3-aminophenyl hemiasterlin payload (SC209) that inhibits tubulin polymerization, causing mitotic arrest and cell death.
Anti-FOLR1 IgG1 antibody (SP8166) binds folate receptor-α on tumor cells, is internalized, and a cathepsin-cleavable linker releases the 3-aminophenyl hemiasterlin payload (SC209), which inhibits tubulin polymerization, inducing mitotic arrest and cell death in FOLR1-expressing cells.
YES
DIRECT
An anti-FOLR1 antibody-drug conjugate binds folate receptor alpha, is internalized, and releases a hemiasterlin payload that inhibits tubulin polymerization, causing mitotic arrest and apoptotic cell death in FOLR1-expressing cells.
An antibody-drug conjugate (STRO-002, Luvelta) targeting folate receptor-α (FOLR1). It consists of an anti-FOLR1 IgG1 (SP8166) linked via a cathepsin-cleavable linker to a 3-aminophenyl hemiasterlin payload (SC209) that inhibits tubulin polymerization, causing mitotic arrest and cell death.
Anti-FOLR1 IgG1 antibody (SP8166) binds folate receptor-α on tumor cells, is internalized, and a cathepsin-cleavable linker releases the 3-aminophenyl hemiasterlin payload (SC209), which inhibits tubulin polymerization, inducing mitotic arrest and cell death in FOLR1-expressing cells.
NO
INDIRECT
The ADC targets FOLR1 on tumor cells, is internalized, and releases a hemiasterlin payload that binds beta-tubulin to inhibit microtubule polymerization, causing mitotic arrest and cell death; killing is driven by FOLR1 targeting, not by beta-tubulin expression itself.
An anti-HER2 antibody–drug conjugate (Enhertu) composed of humanized IgG1 trastuzumab linked to a topoisomerase I inhibitor payload (DXd). It binds HER2 on tumor cells, is internalized, and releases DXd to inhibit topoisomerase I, causing DNA damage and bystander killing; it also retains trastuzumab functions such as ADCC and HER2 signaling blockade.
Humanized anti-HER2 monoclonal antibody (trastuzumab) linked to a topoisomerase I inhibitor (DXd). Binds HER2 on tumor cells, is internalized, and releases DXd to inhibit topoisomerase I, causing DNA damage, replication arrest, and apoptosis with a bystander-killing effect; retains trastuzumab functions including HER2 signaling blockade and antibody-dependent cell-mediated cytotoxicity (ADCC).
YES
DIRECT
The anti-HER2 ADC binds HER2, is internalized, and releases the DXd topoisomerase I inhibitor, causing DNA damage and apoptosis; it also elicits Fc-mediated ADCC and can produce a bystander-killing effect.